CD8A and neoplasm: To investigate whether inhibiting this immunosuppressive pathway might prolong CD8+ T cell activity in the tumour microenvironment, anti-PD-1 treatment was commenced on day 8, before the appearance of PD-1+ CD8+ T cells (day 10) in the YUMMUV1.7 model.